Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib Maintenance in Rectal Cancer
NCT02287727Phase 2Withdrawn
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Mar 2015
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of regorafenib in rectal adenocarcinoma, sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoint: Disease free survival at 3 years. Planned start Mar 2015; status: withdrawn.
02
Drugs
regorafenib
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on NCT02287727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02287727.